Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-05-27 Capital/Financing Update
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
Capital/Financing Update Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces the finalization of an acquisition (Sanofi acquiring Dren Bio's DR-0201 asset) including financial details ($600 million initial payment plus potential future payments). This type of announcement, detailing a significant corporate transaction like an acquisition, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure without a better fit. However, since it details a major financing/transaction event (acquisition payment structure), CAP is a strong candidate. Given the options, M&A Activity (TAR) is for merger proposals or takeover bids, which this is not (it's an acquisition of an asset/subsidiary). Since it involves a significant capital outlay and transaction structure, and is presented as a press release, it fits best under Capital/Financing Update (CAP) as it directly relates to capital structure changes/fundraising activities, although it is also a material event disclosure. Given the focus on the financial terms of the acquisition, CAP is selected over the general RNS.
2025-05-27 French
Press Release: Sanofi completes acquisition of DR-0201
M&A Activity Classification · 100% confidence The document is a press release announcing the completion of an acquisition of a company (Dren Bio, Inc.) and its asset (DR-0201) by Sanofi. This falls under M&A activity, which is categorized as 'TAR' (M&A Activity).
2025-05-27 English
6-K
Regulatory Filings
2025-05-22 English
Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie
M&A Activity Classification · 98% confidence The document is titled "Communiqué de presse" (Press Release) and announces a definitive agreement for Sanofi to acquire Vigil Neuroscience, Inc. This describes a significant corporate transaction involving fundraising, acquisition, or capital structure change, specifically a merger/acquisition. This aligns best with the 'M&A Activity' category (TAR). While it involves financing aspects (the $470 million cash transaction), the core event is the takeover/acquisition proposal, making TAR the most precise fit over CAP. It is not a formal regulatory filing like a 10-K or an earnings release (ER), but rather a public announcement of a major corporate event.
2025-05-22 French
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
M&A Activity Classification · 100% confidence The document is a press release announcing a definitive agreement for Sanofi to acquire Vigil Neuroscience, Inc. It details the financial terms of the merger, including the share price and contingent value rights (CVR), and discusses the strategic rationale for the acquisition. This falls squarely under M&A activity (mergers and acquisitions).
2025-05-22 English
SD
Regulatory Filings
2025-05-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.